Business, energy, technology, markets and global industry news from Business News Today

autosomal dominant polycystic kidney disease

PharmaDeviceNews autosomal dominant polycystic kidney disease
Mezzion’s investigational drug udenafil has reduced kidney cyst burden in an ADPKD animal study, strengthening the scientific rationale for the company’s planned Phase 2b clinical programme. Representative image.
Pharma & Biotech

Mezzion’s new kidney disease data sent shares higher, but the decisive test is still ahead

Mezzion reports animal-model ADPKD data for udenafil as it prepares Phase 2b testing. The findings support development, but human efficacy is unproven.

Read More
Pharma & Biotech

How XORTX is linking gout to genetics and reshaping the future of precision uric acid therapies

XORTX is using new genetic research to strengthen its case for oxypurinol in gout and kidney disease. Find out how this could shape the future of precision nephrology.

Read More